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Molecular modelingFGFRL1 is a single-pass transmembrane proteinwith three extracellular Ig domains.Whenoverexpressed in CHO
cells or related cell types, it induces cell–cell fusion and formation of large, multinucleated syncytia. For this
fusion-promoting activity, only themembrane-proximal Ig domain (Ig3) and the transmembrane domain are re-
quired. It does notmatterwhether the transmembrane domain is derived from FGFRL1 or from another receptor,
but the distance of the Ig3 domain to themembrane is crucial. Fusion can be inhibited with soluble recombinant
proteins comprising the Ig1–Ig2–Ig3 or the Ig2–Ig3 domains as well as with monoclonal antibodies directed
against Ig3. Mutational analysis reveals a hydrophobic site in Ig3 that is required for fusion. If a single amino
acid from this site is mutated, fusion is abolished. The site is located on a β-sheet, which is part of a larger β-
barrel, as predicted by computer modeling of the 3D structure of FGFRL1. It is possible that this site interacts
with a target protein of neighboring cells to trigger cell–cell fusion.
© 2015 Elsevier B.V. All rights reserved.1. Introduction
Cell fusion is the process, bywhich twoplasmamembranesmerge to
becomea single one. In vertebrates, cell fusion is restricted to a very lim-
ited number of cells: it is observed with sperm and egg during fertiliza-
tion, with myoblasts during myotube formation, with macrophages
during bone formation and with trophoblasts during placenta develop-
ment [1,2]. Despite the importance of the process for the survival of all
animals, very little is known about its exact mechanism. Special
fusion-promoting molecules appear to play a decisive role, such as
CD9, CD81 and IZUMO on egg and sperm [3], syncytins on trophoblasts
[4], JamBand JamC onmyoblasts [5], aswell asMFR (macrophage fusion
receptor) and CD47 on macrophages [6,7]. With the exception of
syncytins, which appear to be encoded by genes that have been cap-
tured by mammalian cells from retroviruses during evolution [8], the
fusion-promoting proteins can grossly be grouped into two classes [1,
2,9], namely integral membrane proteins that span the plasma mem-
brane several times (CD9, CD81, CD47) and Ig domain proteins that con-
tain a single transmembrane domain (IZUMO, MFR, JamB, JamC). How
these proteins induce the merger of the two plasma membranes is not
known. In fact, it is still not clear whether the proteins act as truemem-
brane fusogens or rather as highly speciﬁc cell–cell adhesion proteins.artment of Clinical Research,More is known about the fusion of enveloped viruses with the host
cell membrane [10–13]. After an appropriate trigger (pH change or
interaction with a cell surface receptor), viral fusion proteins undergo
dramatic conformational changes, duringwhich a special fusion peptide
becomes exposed, which then is inserted into the host cell membrane.
This event brings the viral membrane into close proximity with the tar-
get membrane. Finally, the two membranes fuse as a result of the close
apposition. Well studied examples of viral fusion proteins are, among
others, hemagglutinin of inﬂuenza virus and the envelope proteins of
ASLV and HIV. Another system that has been extensively studied is the
fusion event of epithelial cells in the nematode Caenorhabditis elegans
[2]. In this case, two fusogens (EFF1 and AFF1) have been described
that share some similarity with viral fusion proteins [14].
We have recently discovered a novel protein, called FGFRL1, that
acts similar to a mammalian fusogen and that has the capacity to fuse
HEK293 cells with CHO cells in culture [15]. FGFRL1 belongs to the fam-
ily of the ﬁbroblast growth factor receptors (FGFRs). Members of this
family contain three extracellular Ig-like domains (Ig1–Ig2–Ig3), a sin-
gle transmembrane domain and a split intracellular tyrosine kinase do-
main. In contrast to the classical FGFR members, FGFRL1 lacks the
intracellular kinase domain but instead contains a short domain of 100
amino acids without clear homology to other proteins [16]. To study
the function of FGFRL1, we have generated knockout animals with a
targeted disruption of the FgfrL1 gene [17]. Such animals are born
alive and develop quite normally until birth, but die within minutes
after birth. They show two major alterations when compared to
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malformed diaphragm. Further studies demonstrated that FGFRL1 is
involved in the transformation of the metanephric mesenchyme into
epithelial renal vesicles as required for the formation of nephrons [18].
Furthermore, FGFRL1 is speciﬁcally involved in the development and
survival of slow muscle ﬁbers in skeletal muscles, a fact that might
explain the malformed diaphragm and the perinatal lethality of
FGFRL1-deﬁcient animals [19].
When we expressed full-length cDNA clones for FGFRL1 in various
cell lines, we noted that our constructs induced rapid fusion of CHO
cells to multinucleated syncytia comprising dozens of nuclei [20]. The
fusion-inducing region of FGFRL1 was characterized with the help of
luciferase and GFP-based reporter assays. These assays revealed that
the Ig3 domain and the transmembrane domain were both necessary
and sufﬁcient for fusion, whereas domains Ig1 and Ig2 as well as the in-
tracellular domain were dispensable for activity. Fusion could be
inhibited with cytochalasin D and latrunculin B, suggesting that actin
polymerization was required during the process. Cell–cell fusion was
observed not only after transfection of our FGFRL1 constructs into
CHO cells, but also after transfection of these constructs into any other
cell line tested (HEK293, 3T3, MG63, HT1080) and subsequent mixing
with CHO cells [20]. In this case, it was sufﬁcient when the FGFRL1 con-
structswere expressed only in theHEK293 cells but not in the CHO cells.
The CHO cells in turn could be replaced by other cells that have the pro-
pensity to spontaneously fuse to larger aggregates, such as CHO-K1,
PgsA-745 and PgsD-677 cells.
Here we further investigated the fusion process induced by FGFRL1.
We found that the fusogenic activity of the Ig3 domain was abolished
when a single amino acid from a hydrophobic pocket of the Ig3 domain
was mutated. It is likely that this site interacts with a target protein of
neighboring cells and that this interaction triggers fusion.
2. Materials and methods
2.1. Cell culture
Various cell lines were obtained from ATCC (American Type Culture
Collection, Manassas, VA USA): CHO-K1 (CCL-61), pgsA-745 (CRL-
2242), pgsC-605 (CRL-2245), HEK-293 (CRL-1573), HEK-293 T (CRL-
11268). HEK-293 TetOn cells were purchased from Clontech Laborato-
ries (Takara Bio Europe/Clontech, Saint-Germain-en-Laye, France). All
cells were grown at 37 °C under an atmosphere of 5% CO2. The culture
medium was DMEM (Dulbecco's modiﬁed Eagle's medium) supple-
mentedwith 10% fetal bovine serum, nonessential amino acids, penicil-
lin (100 units/ml) and streptomycin (100 μg/ml).
2.2. Fusion assay
For a typical fusion experiment, our FGFRL1 constructs were
transfected into HEK293 cells and mixed with CHO cells. To this end,
the DNA constructs (1 μg/106 cells) were incubated for 20 min with
Metafectene (3 μl/μg DNA; Biontex Laboratories GmbH, Munich,
Germany) in 100 μl Opti-MEM (Life Technologies) and then added
dropwise to HEK293 cells that had grown to 70% conﬂuence. After one
day, the cells were collected by trypsinization and mixed with CHO
cells at a 1:5 ratio. Fusion was inspected during the following two
days by phase contrast or epiﬂuorescence (GFP) microscopy. For some
qualitative experiments, the FGFRL1 constructs were also transfected
directly into CHO cells.
For quantitative experiments, HEK293 cells were replaced by
HEK293 TetOn cells (Clontech) since these cells express the Tet
transactivator protein in the presence of doxycycline. In this case, a
luciferase construct with a Tet-inducible promoter (pTRE-Luc,
Clontech) was transfected into the CHO cells, while the FGFRL1 con-
structs were transfected into the HEK293 TetOn cells. After one day,
the two cell populations were mixed and cultivated in the presence of1 μg/ml doxycycline. When fusion of the two cell types occurred, the
Tet transactivator protein diffused from the HEK293 cells to the CHO
cells and activated transcription of luciferase. Luciferase activity was
measured with the Luciferase Assay system from Promega. For this
purpose, cells were lysed in reporter lysis buffer, mixed with luciferase
substrate solution and measured either with a BetaScout luminescence
counter (PerkinElmer Life Sciences, Waltham,MA, USA) or with an Inﬁ-
nite M1000 microplate reader (Tecan Group Ltd., Männedorf,
Switzerland).
2.3. Immunocytochemistry
Cell cultures were chilled on ice, washed twice with cold phosphate
buffered saline (PBS) and ﬁxed for 20minwith 4% paraformaldehyde in
PBS. The cellswere permeabilizedwith 0.2% TritonX-100 in PBS and un-
speciﬁc sites were blockedwith 3% bovine serum albumin (BSA) in PBS.
Subsequently, the cells were stained for 2 h at RT with humanized
monoclonal antibodies against FGFRL1 [21] (1 μg/ml) orwith polyclonal
goat anti-FGFR5 antibodies (R&D Systems, 1:100) in PBS. After three
washing steps with PBS, bound antibodies were detected with second-
ary Cy3-conjugated antibodies (goat anti-human, 1:1000 and mouse
anti-goat, 1:200, Jackson Laboratories Inc.). Nuclei were stained with
4′,6-diamidino-2-phenylindole (DAPI, Invitrogen, 1 μg/ml). Finally, the
cells were mounted with Mowiol and inspected under a Nikon Eclipse
E800 microscope equipped with epiﬂuorescence optics.
2.4. DNA constructs
Various fragments were prepared by PCR from a human FGFRL1
cDNA clone (AJ277437) and a human FGFR1 cDNA clone (IMAGE
clone 3896359) utilizing synthetic DNA primers (Supplemental
Table S1). In order to introduce deletions or to fuse two unrelated
sequences (FGFRL1 and FGFR1), the technique of overlap PCR was
used (Supplemental Table S2) [22]. Likewise, in vitro mutagenesis was
performed by overlap PCR with oligonucleotides that harbored the
desired mutations (Supplemental Table S3). The resulting fragments
were subcloned into pcDNA3.1 (Invitrogen), pEGFP-N1 (Clontech/
Takara) or pSecTag2B (Life Technologies). Authenticity and reading
frame of all constructs were veriﬁed by DNA sequencing.
2.5. Recombinant FGFRL1 protein
The extracellular portion of human FGFRL1was expressed as recom-
binant protein in human cells. For this purpose, the cDNA sequence cor-
responding to amino acids 1–357 (Ig1–Ig2–Ig3) was ligated into the
BamHI/XhoI site of the expression vector pcDNA3.1. HEK293 cells
were transfected with the resulting plasmid and selected with 300 μg/
ml of G418 until resistant colonies became visible (~4weeks). Resistant
colonieswere pooled into a single oligoclonal G418 resistant batch. Sub-
cultures from this batch were grown to conﬂuence, rinsed with PBS and
cultivated in serum-free medium for 3 days. The conditioned media of
the cultures were collected and passed over a column of heparin-
Sepharose (GE Healthcare Europe). After washing of the column with
PBS, bound protein was eluted with 2 M NaCl in PBS.
Alternatively, the cDNA sequence corresponding to amino acids
118–373 (Ig2–Ig3) was ligated into the AgeI/KpnI site of the vector
pSecTag2B (Life Technologies) and transfected into HEK293 cells. In
this case, resistant colonies were selected with 200 μg/ml of Zeocin
(Life Technologies).
2.6. Gel electrophoresis and Western blotting
Proteins were separated under standard conditions on polyacryl-
amide gels containing 5% stacking and 10% running gels. Resolved poly-
peptides were transferred from the gels onto nitrocellulosemembranes
by semi-dry blotting (Trans-Blot SD, BioRad). The membranes were
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with water. Unspeciﬁc sites of the membranes were blocked with 3%
milk powder in PBS. Subsequently, the membranes were incubated
with monoclonal anti-FGFRL1 antibodies overnight at 4 °C. After three
washing steps, alkaline phosphatase-conjugated secondary antibodies
(goat anti-human, 1:10,000, Jackson Laboratories Inc.) were added
and incubated for another hour at room temperature. Finally, bound
antibodies were detected by reaction with 5-bromo-4-chloro-3-
indolyl-phosphate and nitro blue tetrazolium substrate.
2.7. Protein modeling and in-silico mutagenesis
A structural model of the Ig2 and Ig3 domains of human FGFRL1
(NCBI NP_068742, Uniprot Q8N441, amino acids 142–354) was built
using the 3D structures of several FGFRs (PDB# 1IIL, 2FDB, 3GRW,
3OJM and 1EV2) as templates (Supplemental Table S4). Model building
was performed with the programs YASARA [23] and WHATIF [24].
Three rounds of PSI-BLAST iterationswere performed to build a position
speciﬁc scoring matrix, which was then used to ﬁnd suitable templates
in the protein structure database. The templates selected for model
building were of high resolution (b2.5 A) and covered more than 90%
of the target sequence. Secondary structure predictions with the pro-
gram PSI-Pred were used [25] to build the remaining parts of FGFRL1
that were missing in the crystal structures of the templates. For each
of the templates, a separate model was built. The side chains of newly
built parts were optimized by screening of rotamer libraries and by
molecular dynamic simulations to remove steric hindrance created by
homology modeling. Finally, the best parts of the different models
were combined to generate a hybrid model. The resulting hybrid
model had better quality scores than each of the individual models
(overall Z score−0.581). The hybrid model was reﬁned by molecular
dynamic simulation (see below) and checked with the programs
WHATCHECK [26] and WHATIF [24] as well as by Ramachandran plot
analysis (Supplemental Figure S1) [27,28]. Structures were depicted
with Pymol (www.pymol.org).
2.8. Molecular dynamics simulation for model reﬁnement
AMBER03 force ﬁeld was used for molecular dynamic simulations
[23]. The simulation cell was ﬁlled with water; pH was ﬁxed at 7.4
and the AMBER03 [29] electrostatic potentials were evaluated for
water molecules in the simulation cell and subsequently adjusted by
addition of sodium and chloride ions. The ﬁnal molecular dynamic sim-
ulations were then run with AMBER03 force ﬁeld at 298 K, 0.9% NaCl
and pH 7.4 for 1000 ps to reﬁne the models. The best models were
used to analyze and evaluate the effects of mutations introduced into
the FGFRL1 sequence.
3. Results
3.1. Relevance of the transmembrane domain
In a previous publication [20], we demonstrated that a truncated
form of human FGFRL1 comprising the Ig3 domain and the transmem-
brane region induced cell–cell fusion when transfected into CHO cells.
In a domain swapping experiment, we now investigated whether the
transmembrane domain from FGFRL1 was essential or whether the
Ig3 domain would also promote cell–cell fusion in combination with
the transmembrane domain from another receptor. To this end, we
ligated several fragments derived from FGFR1 to fragments from
FGFRL1 and tested the resulting chimeric constructs for fusogenic activ-
ity after transfection into CHO cells (Fig. 1). As expected, FGFR1ΔC
(residues 1–416)was not active in this assay,while FGFRL1ΔC (residues
1–416) showed full activity. When the transmembrane region derived
from FGFRL1 was combined with the extracellular domain from
FGFR1, no cell–cell fusion was observed. However, the constructbecame active, when the portion from FGFRL1 was extended to include
the Ig3 domain as well. Moreover, the extracellular domain of FGFRL1
linked to the transmembrane region of FGFR1 induced cell fusion,
whereas the extracellular domain of FGFRL1 lacking the transmem-
brane region did not. Together, these experiments demonstrate that
the fusogenic activity of FGFRL1 resides within the Ig3 domain and
that the transmembrane can also be derived from another protein.
3.2. Importance of the distance between Ig3 and cell membrane
In the following set of experiments we investigated whether the
distance, by which the Ig3 domain is separated from the plasma mem-
brane, would be important for the fusogenic activity. Constructs were
generated, which had the Ig3 domain of human FGFRL1 directly linked
to the transmembrane region or alternatively, spaced by one or by
two Ig domains from this region (Fig. 2). The fusogenic activity of the
resulting constructs was assessed, after transfection into CHO cells, by
ﬂuorescence emitted from the GFP-tag, which had been added to the
C-terminus. All constructs that had the Ig3 domain placed adjacent to
the transmembrane region were found to be active. It did not matter
whether or not any additional Ig domain was present at the
membrane-distal side of Ig3. In contrast, constructs inwhich the Ig3 do-
main was separated from the transmembrane region by one or by two
Ig domains (constructs Ig3–Ig1–Ig2 or Ig3–Ig2) were inactive in the fu-
sion experiment. Occasionally, the construct with one Ig domain placed
between Ig3 and transmembrane region (construct Ig3–Ig2) showed
some syncytia, but these syncytia never contained more than 4 nuclei.
Thus, the exact distance of the Ig3 domain from the plasma membrane
is crucial for cell–cell fusion activity.
3.3. Inhibition of cell fusion by recombinant FGFRL1 protein
FGFRL1 is known to form dimers and oligomers at the cell surface
[30]. In the third set of experiments, we therefore investigated whether
the soluble extracellular domain of FGFRL1 would inhibit cell–cell
fusion. For this purpose, we prepared recombinant soluble FGFRL1 pro-
tein in HEK293 cells and puriﬁed it by heparin Sepharose as previously
described (30). Recombinant proteins encompassing domains Ig1–Ig2–
Ig3 (not shown) or alternatively Ig2–Ig3 (Fig. 3) were used. Domain Ig3
alone was not prepared because this construct could not be puriﬁed on
heparin Sepharose. Nearly complete inhibition of cell–cell fusion was
obtained when either one of the puriﬁed proteins was added at 50 μg/
ml or 100 μg/ml to a mixture of CHO cells and FGFRL1ΔC transfected
HEK293 cells (Fig. 3A–B). When only bovine serum albumin was
added instead of recombinant protein (control), extensive cell–cell
fusion with formation of large syncytia was observed. An inhibition
rate of approximately 90% was determined when the effect of recombi-
nant FGFRL1 protein (Ig2–Ig3) on cell–cell fusion was quantiﬁed
(Fig. 3C).
3.4. Computer modeling of the 3D structure of FGFRL1
To get some hints about the molecular mechanism of the fusion re-
action induced by FGFRL1, we intended to mutate amino acids of the
fusion-promoting Ig3 domain. In order to select relevant residues, we
generated a 3D model of the extracellular domain of FGFRL1 by homol-
ogy modeling. First, a position speciﬁc iterated BLAST search (PSI-
BLAST) was performed to generate a proﬁle of the FGFRL1 sequence
and to prepare a position speciﬁc scoring matrix (PSSM). This matrix
was then used to search the protein structure database for related struc-
tures. The ﬁve best hits (PDB# 1IIL, 2FDB, 3GRW, 3OJM and 1EV2, Sup-
plemental Table S4) were employed to predict the structure of the Ig2
and Ig3 domains of human FGFRL1. Including only those parts from
the ﬁve models that showed the highest quality, we generated a hybrid
model that covered themaximum of all residues of FGFRL1. This hybrid
model was superior in quality to each of the individual models. Finally,
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Fig. 1. Domains required for the fusogenic activity of FGFRL1. A) Chimeric constructs were prepared, which consisted in part of FGFR1 (blue) and in part of FGFRL1 (orange). Construct 1
corresponded to pure FGFR1ΔC; construct 5 to pure FGFRL1ΔC. The resulting constructswere transfected into CHO cells and cell–cell fusionwas judged one day later under themicroscope
(indicated by+and−). Each construct, which contained the Ig3 domain of FGFRL1, induced cell–cell fusion, regardless ofwhether the other domains (Ig1, Ig2, TM) originated from FGFR1
or FGFRL1. In particular, it did notmatterwhether the transmembrane domain (TM)was derived from FGFR1 or FGFRL1. Thus, the fusogenic activity must residewithin the Ig3 domain of
FGFRL1. B) Representative images of CHO cells transfected with either one of the six different constructs shown in panel A. Bar = 100 μm.
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namics simulation of all amino acid side chains. Examination of the
ﬁnal model by Ramachandran plot analysis demonstrated that 98% of
all residues occurred in favored regions and that 100% of all residues
were located in allowed regions (Supplemental Figure S1).
The ﬁnal model of FGFRL1 Ig2–Ig3 (Fig. 4) revealed that each of the
two Ig domains formed a typical β-barrel. Each β-barrel consisted of 7
anti-parallel β-strands that contained two layers of β-sheets. Our struc-
ture was highly similar to the structures of human FGFR1 and human
FGFR2 that had been solved by X-ray crystallography [31]. Interestingly,
our model also predicted an extended, seemingly ﬂexible loop locatedbetween β-strands C and D, which bulged out from the Ig3 domain of
FGFRL1. The published structures of FGFR1 and FGFR2 also contained a
loop between β-strands C and D, but in those structures the loop was
much smaller (Fig. 4C).
3.5. Mutational analysis
Based on the structural model of FGFRL1, 18 amino acid residues
were selected for in vitro mutagenesis (Table 1, Fig. 4B). Residues
around P315 were selected because this region showed remote similar-
ity to the fusion peptides of some viruses [11,12,32]. In avian sarcoma/
Ig
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Fig. 2. Importance of the distance between Ig3 and the cell membrane. FGFRL1ΔC-GFP constructs were prepared, which contained the fusogenic Ig3 domain directly linked to the trans-
membrane domain or alternatively, spaced from the transmembrane domain by one or by two Ig domains as indicated. The resulting constructs were transfected into CHO cells and cell–
cell fusion was analyzed one day later by ﬂuorescence emitted from the GFP-tag. Each construct that had the Ig3 domain linked directly to the transmembrane domain induced cell–cell
fusion. However, fusogenic activity was virtually abolished when one or two Ig domains were inserted between Ig3 and the transmembrane domain. Bar = 100 μm.
2277L. Zhuang et al. / Biochimica et Biophysica Acta 1853 (2015) 2273–2285leukosis virus (ASLV) for example, this fusion peptide harbors a crucial,
central proline residue that is ﬂanked by a β-sheet and an α-helix [33].
Residues E289–N293 were selected because they formed the extra loop
that bulged out from the Ig3 domain. ResidueN293was chosen because
it represents the attachment site for carbohydrates (293-NST-295). A
glycosylation site has been suggested to play a role in the fusion event
of sperm and egg that is promoted by IZUMO [3]. Finally, residuesL281, F303, V304 and L339 were chosen because they form a conspicu-
ous hydrophobic pocket, which is shielded by the putative ﬂexible loop
of Ig3.
The selected residues were mutated, either alone or in groups ac-
cording to Table 1, and the resulting constructs were tested for their
fusion-promoting activity after transfection into CHO cells (Fig. 5). We
found that most of the mutations barely inﬂuenced the fusogenic
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Fig. 3. Inhibition of fusogenic activity by recombinant soluble FGFRL1 protein. A) Cell–cell fusionwas induced bymixing CHO cells with HEK293 cells, which had been transfected with an
FGFRL1ΔC-GFP construct. After 8 h, the cells were ﬁxed, stained with DAPI and checked for fusion by ﬂuorescence emitted from the GFP tag. Fusion could be inhibited by addition of re-
combinant soluble FGFRL1 protein (containing domains Ig2–Ig3) to the cell culture media at 50 or 100 μg/ml. Recombinant protein containing domains Ig1–Ig2–Ig3 had the same effect
(not shown). Bar = 100 μm. B) Purity of our recombinant protein Ig2–Ig3 was checked on an SDS polyacrylamide gel in the presence of mercaptoethanol. To check for the presence of
recombinant protein in the cell cultures, aliquots (20 μl) of the conditioned media were separated by PAGE (in the absence of reducing agents) and transferred to a nitrocellulose mem-
brane. The membrane was stained with Ponceau Red and incubated with a monoclonal antibody against FGFRL1, followed by alkaline phosphatase-conjugated secondary antibodies.
C) Quantiﬁcation of the experiment from panel A showed that recombinant protein Ig2–Ig3 inhibited cell–cell fusion by about 90% when added at 100 μg/ml.
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Fig. 4. Prediction of 3D structure of FGFRL1 and selection of individual amino acids for in vitromutagenesis. A) Ribbonmodel of FGFRL1. The structure of the extracellular domain of human
FGFRL1 (Ig2–Ig3)was predicted by computermodeling (see Section 2). Each of the Ig domainswas found to consist of a β-barrel,whichwas formed by 7 anti-parallelβ-strands (termedA
to G in FGFR1, indicated by arrows). The polypeptide backbone is shown as ribbonmodel with spectral coloring from violet (N-terminus) to red (C-terminus). Note that domain Ig3 con-
tains a prominent loop between β-strands C and D (orange-yellow) that bulges out from the β-barrel. B) Location of amino acids selected for mutational analysis. The side chains of se-
lected residues are numbered and shown in red (affecting cell–cell fusion) or green (not affecting cell–cell fusion, see further below). C) Alignment of the FGFRL1model (rainbow colors)
with the X-ray crystal structures of FGFR1 (pink) and FGFR2 (gray). The distinctive loop in the Ig3 domain of FGFRL1 is almost completely missing in the structures of FGFR1 and FGFR2.
Images were prepared with Pymol (www.pymol.org) and rendered as ray traced images using POV-RAY (www.povray.org).
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activity, namely L281S, F303S and L339S. In addition, mutation V304S
showed a moderate effect on cell–cell fusion. Interestingly, all these
four residues were situated within the hydrophobic pocket of Ig3
described above (Fig. 6).
Tomeasure the effect of the three mutations, we used a quantitative
test. This test involved a luciferase construct, which was under the con-
trol of the Tet-transactivator protein. CHO cells were transfected with
the luciferase construct and mixed with HEK293 TetOn cells, which
expressed the Tet transactivator protein and which had been
transfected with either one of the mutated FGFRL1 constructs. Lucifer-
ase was produced only after the CHO cells had fused with the HEK293Table 1
Mutational analysis of FGFRL1.
Mutation Fusogenic activity
D273A +
K275A +
L281S −
289EGRHN-GAGKL293 +
N293Q +
F303S −
V304S +/−
303FVV-GGG305 −
P307G +
V311G +
W312G +
R314G +
P315L +
D316A +
L339S −cells and mixed their cytoplasm containing the transactivator protein.
With this quantitative assay, each of the three constructs L281S, F303S
and L339S showed less than 10% fusogenic activity when compared to
wildtype FGFRL1 or to the D273A construct (Fig. 5B). Mutation V304S
showed about 50% fusogenic activity. Thus, the four mutations demar-
cate the “active site” of the FGFRL1 protein that is required for cell–cell
fusion (Fig. 6). In our 3D model of human FGFRL1, this site is marked
in red in contrast to other sites marked in green, whose mutations did
not affect fusogenic activity.
3.6. Localization of the mutated proteins at the cell surface
A trivial explanation for the inhibiting effect of the four mutations
would be that they induced a conformational change of the Ig3 domain,
which was not compatible with expression, translocation and/or inser-
tion of the corresponding polypeptides into the cell membrane. To ex-
clude this possibility, we analyzed the subcellular distribution of the
mutated proteins in HEK293 cells by ﬂuorescent microscopy, utilizing
theGFP-tag that had been linked to the C-terminus (Fig. 7). This analysis
demonstrated that all of the four constructswere nicely presented at the
cell membrane similar to the wildtype protein and the inactive D273A
mutant. In addition to the ﬂuorescence at the cell membrane, some
signal was also noted at intracellular structures, probably the Golgi net-
work [21].
Next, we conﬁrmed the surface distribution of the mutated proteins
with polyclonal antibodies directed against FGFRL1.When added to the
cultures prior to cell permeabilization, the antibodies yielded staining
patterns (red) with all constructs that looked very similar to the surface
distribution of the GFP signal (green). Superposition of the ﬂuorescent
signals emitted from GFP and from the antibodies produced a yellow
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Fig. 5. Effect of selectedmutations on fusogenic activity of FGFRL1. A) FGFRL1ΔC-GFP con-
structs harboring various mutations in Ig3 were transfected into HEK293-TetOn cells. In
parallel, CHO cells were transfected with a luciferase construct (pTRE-Luc) containing a
Tet-inducible promoter. After one day, the two cell populations were combined. Another
day later, the cells were ﬁxed, stained with DAPI and inspected under the microscope.
Large syncytia were observed with the wildtype and the D273A construct. Mutations
L281S, F303S and L339S completely inhibited syncytia formation; mutation V304S
showed moderate inhibition. Bar = 100 μm. B) The effect of somemutations was quanti-
ﬁed utilizing the luciferase assay system. Cells were lysed,mixedwith luciferase substrate
andmeasured in a luminometer. Mutations L281S, F303S and L339S inhibited cell–cell fu-
sion by more than 90%; mutation V304S showed 50% inhibition.
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proteins were faithfully expressed and incorporated into the plasma
membrane (Fig. 7). Of course, the antibodies did not stain the intracel-
lular structures because they were added prior to cell permeabilization.
Finally, the four mutations were also checked in our 3Dmodel by in
silico analysis. Computational mutagenesis of FGFRL1 did not reveal any
structural changes for the mutated proteins L281S, F303S, V304S and
L339S. All proteins had overall structures and folds similar to the
wildtype protein.
3.7. Inhibition of cell fusion by monoclonal antibodies
We also repeated the distribution experiment with twomonoclonal
antibodies (AB3, AB4) that had been prepared against recombinantFGFRL1 in a previous study [21]. These antibodies recognize a conforma-
tional epitope and do not react with FGFRL1 after reduction of disulﬁde
bonds. This time, we added the antibodies after cell permeabilization.
With the wildtype protein and the constructs D273A, V304S and
L339S, ourmonoclonal antibodies produced a staining pattern very sim-
ilar to the polyclonal antibodies (Fig. 8). Again, superposition of the GFP
signal (green) and the signal from the antibodies (red) gave a yellow
pattern along the surface of the transfected cells. However, to our sur-
prise neither of the two monoclonal antibodies detected the mutated
proteins L281S and F303S. It is therefore likely that the epitope recog-
nized by our monoclonal antibodies exactly included residues L281
and F303.
Since L281 and F303 are located at the “active site” of the fusogenic
Ig3 domain and since our monoclonal antibodies appear to interact ex-
actlywith these amino acids, it was likely that our antibodieswould also
inhibit cell–cell fusion. In fact, when we performed a quantitative cell
fusion experiment, we could block the fusion event with either one of
the two antibodies (Fig. 9). When compared to a control where we
had added unspeciﬁc IgG, our monoclonal antibodies showed an inhib-
itory effect of about 85%. When the two antibodies were added in con-
cert, no additive effect was noted, suggesting that AB3 and AB4
recognize the same site.
Taken together, the mutational analysis and the antibody blocking
experiment strongly suggest that the hydrophobic pocket of the Ig3 do-
main represents the crucial site that is required for cell–cell fusion in
CHO cells.
4. Discussion
FGFRL1 is a transmembrane receptor found in low quantities on the
surface of most mammalian cells. When overexpressed in CHO or CHO-
related cells, it can induce cell–cell fusion. FGFRL1-transfected CHO cells
have therefore become a versatile model in our laboratory to study the
molecular mechanism of cell fusion.
In this publication we have shown that only the Ig3 domain of
FGFRL1 is required for fusion and that this domain has to be linked to
a transmembrane domain and kept in close apposition to the cell mem-
brane. The origin of the transmembrane domain (i.e. whether it origi-
nates from FGFRL1 or from FGFR1) does not matter. However, the
distance of the Ig3 domain to the plasma membrane is of importance.
When this distance is increased, fusion activity is lost. Fusion can be
blocked by recombinant, soluble FGFRL1 protein aswell as bymonoclo-
nal antibodies directed against the Ig3 domain. We have also been able
to localize three amino acid residues that togethermight forman “active
site”, which is required for cell fusion. All these residues occur at the sur-
face of a hydrophobicβ-sheet.When a single amino acid from this site is
mutated, fusogenic activity is abolished. The fact that each of the three
amino acids has a similar effect although they are located on different
β-strands (Fig. 6) lends credibility to the 3D structure of FGFRL1,
which was predicted by computer modeling.
What is the function of this “active site” or, in otherwords, howdoes
FGFRL1 bring about cell–cell fusion? Since the site is formed by a β-
sheet, which is part of a larger β-barrel, it is not likely that the mecha-
nism involves a fusion peptide as they are found in many enveloped vi-
ruses. In such viruses, the fusion peptides are hydrophobic stretches of
16–26 residues that usually form an α-helix, which is inserted into the
host cell membrane after cell fusion has been triggered [33].
We rather think that the “active site” might interact with a mem-
brane protein from neighboring cells and that this interaction triggers
the fusion event. Thus, the process has several aspects in common
with fusion of a viral membrane with the host cell. In the case of retro-
viruses, fusion is known to be accomplished by an envelope protein that
represents one of the constituents of the viral coat [12,32]. Retroviral
envelope proteins are large polypeptides consisting of two subunits, a
surface subunit SU and a transmembrane subunit TM that are linked
by a disulﬁde bond. The SU domain interacts with a receptor molecule
A B C
Fig. 6. Active site of human FGFRL1. A) Surface model of domains Ig2 and Ig3. Mutations that affected cell–cell fusion are shown in red, mutations that did not affect cell–cell fusion in
green. Mutation V304S, which had a moderate effect, is shown in magenta. In the online version of the paper, this model can be rotated around its axis (supplemental movie).
B) Close-up of the “active site” in the Ig3 domain of FGFRL1. Amino acids L281, F303, V304 and L339 come close together to form the “active site” in the 3D structure, although they
are located far apart from each other in the primary sequence. C) Combination of surface structure and ribbon model of Ig3. While V304 is somewhat buried within the active site, the
side-chains of L281 and F303 contribute to the surface of the “active site” and might represent potential interaction partners.
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cell membrane. During fusion, the entire complex undergoes a confor-
mational rearrangement and propels the SU domain into the host cell
membrane.
If FGFRL1 did indeed interact with a viral envelope protein of target
cells, it would represent the receptor for the corresponding virus. In fact,
a genome-wide search for proteins related to the structure of FGFRL1
with three Ig domains and a transmembrane region yielded, in addition
to members of the FGFR family, members of the nectin and the SIGLEC
family as best hits [34]. Interestingly, Nectin-1 and nectin-2 are known
to function as entry receptors for herpes simplex virus and pseudorabies
virus. Nectin-like protein 5 is the receptor for poliovirus. Furthermore,
Siglec1 mediates attachment and internalization of porcine reproduc-
tive and respiratory syndrome virus (PRRSV).
It has been established that a fraction of 8–10% of the human and the
mouse genome is derived from retroviral sequences [35]. It is therefore
conceivable that our target cells, the CHO cells, express a retroviral en-
velope protein on their surfaces. In fact, other researchers have identi-
ﬁed retrovirus-like sequences in CHO cells [36]. Moreover, the genome
of CHO cells harbors multiple copies of a gene for an envelope protein
that is closely related to the envelope proteins from mouse leukemia
virus (MLV) and feline leukemia virus (FLV) (http://pre.ensembl.org/
Cricetulus_griseus). Most of these sequences are defective and contain
frameshift errors or stop codons disrupting the open reading frame,
but there are some examples with large open reading frames (e.g.
XP_007622324, XP_007625005).
We have investigated the possibility that FGFRL1 would interact
with such an endogenous envelope protein, but so farwe have obtained
only negative results. 1) The CHO cells have been analyzed for the pres-
ence of viral reverse transcriptase, but no reverse transcriptase activity
could be detected. 2) Media conditioned by actively fusing cells or syn-
cytia were added to HEK293 and CHO cells that had been transfected
with our fusogenic FGFRL1 constructs, but no cell fusion was observed.
3) The putative envelope protein was cloned from genomic DNA of
CHO cells (XM_007624134) and expressed in CHO cells and FGFRL1
transfected HEK293 cells. No cell–cell fusion was noted. 4) Expression
of the putative envelope protein was down-regulated in CHO cells by
siRNA. Absolutely no inhibition of FGFRL1-induced cell–cell fusion was
observed. 5) Finally, we tested the effect of peptides that were designed
according to the heptad-repeat region of the TM protein from retrovi-
ruses. Such heptad-repeat peptides have been shown to inhibit viral in-
fection in the case of HIV [37] and FLV [38]. Utilizing polypeptides withproven inhibitory activity for HIV and FLV as well as peptides designed
according to the putative heptad-repeat of the envelope protein from
CHO cells, we were not able to inhibit cell–cell fusion induced by
FGFRL1. Taken together, it is therefore unlikely that a retroviral protein
similar to the envelope protein of MLV or FLV can trigger cell fusion in
combination with FGFRL1.
Another possibility would be that FGFRL1 affects the structure of the
plasmamembrane. It has been demonstrated that membrane curvature
is involved in cell fusion processes; themore curved amembrane is, the
more fusogenic it becomes [39,40]. It is therefore conceivable that
FGFRL1 induces the formation of a structure with high curvature, such
as microvilli or nanotubes, on the surface of fusion-competent cells.
These structures might trigger fusion with neighboring cells and this
process might proceed in an autonomous fashion, especially in cell
types that have a low energy barrier to undergo fusion, such as CHO-
like cells. Indeed, we observed that recombinant FGFRL1 protein has a
tendency to aggregate and precipitate [41]. If present in high concentra-
tions at the cell membrane, FGFRL1 [42] aswell as the fusogenic protein
CD9 aggregate to net-like structures [43]. Such net-like structures
appear to promote the formation of microvilli-like protrusions bulging
out from the cell membrane as demonstrated by electron microscopy
[43]. This theory would explain why CHO cells do not fuse when they
express physiologically low levels of FGFRL1, but why they become
fusogenic after overexpression of FGFRL1. It has been estimated that
about 30% of the area of the membrane surface has to be covered by Ig
domains (or by C2 domains) in order to induce a nanotube with high
curvature [40]. We therefore propose that in a ﬁrst step, FGFRL1 forms
aggregates at the surface of a fusion competent cell and promotes for-
mation of a membrane structure with high curvature. In a second step,
FGFRL1 might interact with a target protein of neighboring cells. This
interaction might bring the target membrane into close apposition as
required for membrane fusion.
There is circumstantial evidence in favor of the second hypothesis. Ig
domains similar to Ig3 of FGFRL1 appear to be a common feature of pro-
teins required for cell fusion. They occur for example in the sperm-egg
fusion protein IZUMO [3], in the macrophage fusion receptor MFR [6],
in the fusion-inducing leukocyte surface antigen CD47 [7] and in the
myoblast fusion proteins DUF, RST and SNS from Drosophila [44]. A sim-
ilar structure is also found in synaptotagmins, proteins that are involved
in intracellular fusion events [39]. Moreover, it has been demonstrated
that FGFRL1 is involved in cell–cell tethering processes. This is the case
during embryonic development of muscles when myoblasts align and
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Fig. 7. Localization of mutated FGFRL1 proteins at the cell membrane. FGFRL1ΔC-GFP constructs harboring various mutations as indicated were transfected into HEK293T cells. After one
day, the cellswereﬁxedand incubatedwith polyclonal antibodies against FGFRL1 (prior to cellmembranepermeabilization), followedbyCy3-labeled secondary antibodies (red) andDAPI
(blue). The ﬂuorescence signal emitted from FGFRL1ΔC-GFP (green) localized to the plasmamembrane and to some intracellular structures (probably Golgi). The signal emitted from the
antibodies (red) colocalized with the GFP signal to a large extent, yielding a yellow signal at the cell membrane in merged pictures. Bar = 50 μm.
2282 L. Zhuang et al. / Biochimica et Biophysica Acta 1853 (2015) 2273–2285
D273A
L281S
F303S
V304S
L339S
WT
MergeABGFP
Fig. 8. Visualization of FGFRL1ΔC-GFP constructs in human cells withmonoclonal antibodies. HEK293T cells were transfectedwith FGFRL1ΔC-GFP constructs as described in the legend to
Fig. 7. After one day, the cells were ﬁxed, permeabilized and incubated with a monoclonal antibody (AB4) against FGFRL1. Red ﬂuorescent signal (indicative of bound antibodies) was
observedwith the wildtype protein and with constructs D273A, V304S and L339S, but not with constructs L281S and F303S. AB3 gave very similar results to AB4 (not shown). The signal
emitted from the antibodies colocalized with the signal emitted from FGFRL1ΔC-GFP, producing a yellow signal in merged pictures. Bar = 50 μm.
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Fig. 9. Cell–cell fusion is inhibited by monoclonal antibodies against FGFRL1. Human
FGFRL1ΔC was transfected into HEK293 TetOn cells. At the same time, a GFP construct
with a Tet-inducible promoter [20] was transfected into CHOpgsA cells. One day later,
the two cell populations were combined and cultivated on microtiter plates in the pres-
ence of 1 μg/ml doxycycline and 1 μg/ml monoclonal antibodies against FGFRL1 (human-
ized clones AB3 and AB4 [21]). After 16 h, the ﬂuorescence signal emitted from GFP was
measured with a microplate reader. The bars show relative fusion activity from triplicates
with standard deviation. All controls contained 1 μg/ml of human IgG. The monoclonal
antibodies against FGFRL1 inhibited cell fusion by about 90%.
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chymal cells of the metanephric mesenchyme aggregate and undergo a
transformation to renal vesicles [18]. It is conceivable that under non-
physiological conditions, e.g. after forced overexpression of FGFRL1 in
cell culture, this cell–cell tethering process does not properly stop but
continues until two cell membranes have completely merged.
To better understand the molecular mechanism of the fusion reac-
tion induced by FGFRL1 and in order to support or dismiss either one
of the two hypotheses described above, it is inevitable to identify the
target protein, to which FGFRL1 binds. Utilizing liquid chromatography
in combination with mass spectrometry, we tried to identify proteins
that speciﬁcally interact with the Ig3 domain of FGFRL1 [20]. While
we could identify proteins that interact with the Ig2 domain
(glypican-4 and -6),wewere not able to identify any interaction partner
of the Ig3 domain.We had to include relatively strong detergents to pre-
pare protein extracts from cell membranes, which then were passed
over columns containing recombinant Ig3 coupled to Sepharose. It is
therefore possible that these detergents abolished any interaction of a
membrane protein with the hydrophobic site of Ig3. A different experi-
mental approach will therefore be required to identify the true target of
the fusion-inducing Ig3 domain.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.bbamcr.2015.05.027.
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